LNCD(SH:600739)2020-10-30 16:00Financial Performance - Operating income for the first nine months was CNY 12.38 billion, a decrease of 10.24% compared to the same period last year[4] - Net profit attributable to shareholders of the listed company was CNY 2.53 billion, representing a significant increase of 142.16% year-on-year[4] - Basic earnings per share reached CNY 1.6514, an increase of 142.14% compared to the same period last year[4] - The company's net profit attributable to shareholders was RMB 14.91 billion, compared to RMB 12.54 billion at the end of 2019, reflecting an increase of about 19%[15] - The company's operating profit for Q3 2020 was approximately ¥1.67 billion, a significant increase from ¥404.76 million in Q3 2019, representing a growth of 313%[20] - Net profit for Q3 2020 reached approximately ¥1.59 billion, compared to ¥353.38 million in Q3 2019, marking an increase of 348%[20] - The total comprehensive income for Q3 2020 was approximately ¥1.52 billion, up from ¥562.36 million in Q3 2019, reflecting a growth of 169%[21] - The company achieved a profit attributable to shareholders of approximately ¥1.58 billion in Q3 2020, compared to ¥292.46 million in Q3 2019, an increase of 440%[20] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 39.69 billion, an increase of 1.15% compared to the end of the previous year[4] - Cash and cash equivalents increased by 46.82% to CNY 3,132,703,563.91 compared to CNY 2,133,730,165.92 in the previous year[8] - Inventory decreased by 35.99% to CNY 1,387,183,047.98 from CNY 2,167,214,138.38 year-on-year[8] - Total current liabilities decreased to RMB 9.65 billion from RMB 10.30 billion, representing a reduction of about 6.3%[14] - The total liabilities of the company decreased to RMB 14.61 billion from RMB 16.30 billion, a reduction of approximately 10.4%[15] - The total assets amounted to ¥39,234,272,364.98 as of the reporting date[30] - The total current liabilities were reported at ¥6,702,005,400.00[30] - Total liabilities amounted to ¥16,295,323,496.28, unchanged from the previous period[31] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 671.12 million, up 59.25% from the previous year[4] - Cash flow from operating activities for the first three quarters of 2020 was approximately CNY 11.08 billion, down from CNY 11.95 billion in the same period of 2019, showing a decrease of about 7.3%[25] - The net cash flow from investing activities for Q3 2020 was approximately CNY 2.08 billion, a significant improvement compared to a negative cash flow of CNY 455.77 million in Q3 2019[26] - The net cash flow from financing activities for Q3 2020 was negative CNY 1.55 billion, compared to a negative cash flow of CNY 617.78 million in the same quarter of the previous year, indicating a worsening of financing conditions[26] - The ending balance of cash and cash equivalents increased to ¥3,113,639,118.81 from ¥1,650,644,213.47[27] - Net cash flow from operating activities was -¥135,971,140.33, an improvement from -¥452,147,693.25 in the same period last year[27] Shareholder Information - The total number of shareholders at the end of the reporting period was 75,362[5] - The largest shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., held 12.61% of the shares, with a total of 192.90 million shares[6] Research and Development - Research and development expenses rose by 104.18% to CNY 160,789,977.95 compared to CNY 78,748,334.86 in the previous year[8] - Research and development expenses increased to ¥47,999,605.97 in Q3 2020, compared to ¥27,834,507.32 in Q3 2019, reflecting a growth of 72.5%[19] Tax and Other Expenses - The company reported a 36.15% increase in income tax expenses to CNY 168,452,823.35 from CNY 123,727,297.34 year-on-year due to increased profits from subsidiaries[9] - The company reported a tax expense of approximately CNY 476.51 million for Q3 2020, compared to CNY 3.71 billion in Q3 2019, indicating a significant reduction in tax liabilities[23] Corporate Actions - The company plans to spin off its subsidiary Liaoning Chengda Biological Co., Ltd. for listing on the Sci-Tech Innovation Board, with the application formally accepted by the Shanghai Stock Exchange[10] - The company disposed of its subsidiary Chengda Fangyuan, resulting in a significant impact on goodwill, which decreased to CNY 0.00 from CNY 84,757,720.17[8] - The company has completed the transfer of all shares of Chengda Fangyuan to Guoda Pharmacy, with the registration process finalized on July 30, 2020[10] Investment Income - Investment income increased by 150.56% to CNY 2,785,330,523.84 from CNY 1,111,642,294.52 year-on-year[8] - Net profit from investment for Q3 2020 was ¥1,690,271,774.89, significantly up from ¥258,439,250.53 in Q3 2019[19] - Investment income for Q3 2020 was approximately ¥2.02 billion, significantly higher than ¥262.22 million in Q3 2019, representing an increase of 669%[22]